Search results for "Randomized controlled"

showing 10 items of 2220 documents

Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma.

2007

An inhaled corticosteroid (ICS) or an ICS/long-acting beta(2)-agonist (LABA) combination plus short-acting beta(2)-agonist (SABA) as needed for symptom relief is recommended for persistent asthma. Additionally, budesonide/formoterol maintenance and reliever therapy (Symbicort SMART, AstraZeneca, Sweden) has been approved for adults in the European Union. This option is well tolerated and offers greater reductions in asthma exacerbations together with similar improvements in daily symptom control, at a lower overall steroid load, compared with fixed-dose ICS/LABA plus SABA.Two large clinical trials investigated the use of budesonide/formoterol as maintenance and reliever compared with medium…

BudesonideAdultMalemedicine.medical_specialtyAdolescentlaw.inventionPlacebosRandomized controlled trialDouble-Blind MethodlawInternal medicineFormoterol Fumaratemedicinemedia_common.cataloged_instanceHumansAnti-Asthmatic AgentsEuropean unionBudesonidemedia_commonAsthmaAgedRandomized Controlled Trials as TopicAged 80 and overbusiness.industryGeneral MedicineAdrenergic beta-AgonistsMiddle Agedmedicine.diseaseClinical trialTreatment OutcomeBudesonide/formoterolEthanolaminesPhysical therapyFormoterol FumarateDrug Therapy CombinationFemaleFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugCurrent medical research and opinion
researchProduct

Overall asthma control: the relationship between current control and future risk.

2009

Background Asthma guidelines emphasize both maintaining current control and reducing future risk, but the relationship between these 2 targets is not well understood. Objective This retrospective analysis of 5 budesonide/formoterol maintenance and reliever therapy (Symbicort SMART Turbuhaler ∗ ∗Symbicort SMART and Turbuhaler are trademarks owned by AstraZeneca. Neither the Symbicort SMART posology nor the dry powder formulation Turbuhaler are currently approved in the United States.) studies assessed the relationship between asthma control questionnaire (ACQ-5) and Global Initiative for Asthma-defined clinical asthma control and future risk of instability and exacerbations. Methods The perc…

BudesonideAdultMalemedicine.medical_specialtyExacerbationAdolescentImmunologyYoung AdultAdrenal Cortex HormonesInternal medicineFormoterol FumarateSurveys and QuestionnairesAdministration InhalationmedicineImmunology and AllergyBudesonide Formoterol Fumarate Drug CombinationHumansAnti-Asthmatic AgentsRisk factorBudesonideChildAsthmaAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overInhalationbusiness.industryAdrenergic beta-AgonistsMiddle Agedmedicine.diseaseAsthmaMarkov ChainsDrug CombinationsAsthma Control QuestionnaireEthanolaminesChild PreschoolPractice Guidelines as TopicPhysical therapyFormoterol FumarateFemaleFormoterolbusinessmedicine.drugThe Journal of allergy and clinical immunology
researchProduct

Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial

2003

Summary Background : The role of mesalazine in preventing the clinical recurrence of Crohn's disease after surgery has been shown in a meta-analysis of all published studies. No clear relationship, however, has been shown between dosage and response. Aim : To evaluate whether 4.0 g/day of mesalazine may offer therapeutic advantages over 2.4 g/day in the prevention of both endoscopic and clinical post-operative recurrence of Crohn's disease. Methods : The study was a double-blind, randomized, multi-centre, prospective, controlled clinical trial. Two hundred and six patients, submitted to first or second intestinal resection for Crohn's disease limited to the terminal ileum, with or without i…

BudesonideCrohn's diseasemedicine.medical_specialtyHepatologymedicine.diagnostic_testbusiness.industryGastroenterologymedicine.diseaseGastroenterologylaw.inventionEndoscopyClinical trialchemistry.chemical_compoundRegimenMesalazinechemistryRandomized controlled triallawInternal medicineMedicineAscending colonPharmacology (medical)businessmedicine.drugAlimentary Pharmacology & Therapeutics
researchProduct

Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations

2017

Asthma has been demonstrated to be as common in the elderly as in younger age groups. Although no specific recommendations exist to manage the disease differently in older individuals, functional features and clinical presentations may be affected by age per se, and by age-related conditions, such as comorbidities and polypharmacy. In this review article, we aimed to explore the efficacy and safety in elderly asthmatic patients of one of the most currently used inhaled treatments for asthma, that is, the fixed-dose combination of budesonide/formoterol. We attempted to address some practical questions that are relevant to the daily practice of clinicians. We focused on the efficacy and real-…

BudesonideGeriatrics & GerontologyDatabases Factuallaw.invention0302 clinical medicineRandomized controlled trialRELIEVER THERAPYlawBudesonide Formoterol Fumarate Drug CombinationDrug InteractionsPharmacology (medical)Anti-Asthmatic AgentsPharmacology & Pharmacy030212 general & internal medicineEMPHYSEMATOUS LUNGSGeriatricsPRIMARY-CAREGeriatrics and Gerontology Pharmacology (medical)Middle AgedRANDOMIZED CONTROLLED-TRIALSINGLE INHALERTreatment OutcomeDrug InteractionPractice Guidelines as TopicLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato RespiratorioOBSTRUCTIVE PULMONARY-DISEASE03 medical and health sciencesAdministration InhalationmedicineAnti-Asthmatic AgentHumansOLDER-PEOPLEIntensive care medicineAgedAsthmaPolypharmacyAIRWAY CLEARANCEScience & Technologybusiness.industryDRY POWDER INHALERSmedicine.diseaseAsthma030228 respiratory systemBudesonide/formoterolLUNG DEPOSITIONGeriatricsPhysical therapyIndacaterol1115 Pharmacology And Pharmaceutical SciencesFormoterolGeriatrics and GerontologybusinessDrugs & Aging
researchProduct

Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: A non-inferiority, randomised, double-blind clinical tr…

2015

Summary Background Treatment guidelines for patients with moderate persistent asthma recommend regular therapy with a combination of an inhaled corticosteroid and a longacting β 2 agonist plus as-needed rapid-acting bronchodilators. We investigated whether symptom-driven budesonide and formoterol combination therapy administered as needed would be as effective as regular treatment with this combination plus as-needed symptom-driven terbutaline for patients with moderate asthma. Methods In this non-inferiority randomised clinical trial, we recruited adult patients (18–65 years of age) with stable moderate persistent asthma, according to 2006 Global Initiative for Asthma guidelines. Patients …

BudesonideMalePediatricsKaplan-Meier Estimatelaw.inventionRandomized controlled triallawMedicineOutpatient clinicBudesonide Formoterol Fumarate Drug CombinationAnti-Asthmatic AgentsTreatment Failureeducation.field_of_studyasthma; clinical trialMedicine (all)clinical trialMiddle AgedCombined Modality TherapyBronchodilator AgentsFemalemedicine.drugHumanAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentTerbutalinePopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPlaceboDrug Administration ScheduleNOYoung AdultDouble-Blind MethodAdministration InhalationTerbutalineinhaled corticosteroids LABA asthma clinical trialHumansAnti-Asthmatic AgenteducationBronchodilator AgentPulmonary and Respiratory Medicine; Medicine (all)AsthmaAgedPulmonary and Respiratory Medicine RCT asthmabusiness.industryComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKSmedicine.diseaseAsthmarespiratory tract diseasesFormoterolbusiness
researchProduct

Low-dose budesonide treatment for prevention of postoperative recurrence of Crohnʼs disease

1999

Summary and ConclusionAlthough the effect of budesonide was altogether positive in almost all variables studied in this train (e.g. endoscopic and histopathological score, time-to-failure, CDAI, patients' global judgement and rate of side effects), this increase in efficacy was small and the power f

Budesonidemedicine.medical_specialtyCrohn's diseaseHepatologymedicine.diagnostic_testbusiness.industrymedicine.drug_classGastroenterologyPlacebo-controlled studyColonoscopymedicine.diseaseGastroenterologylaw.inventionSurgeryClinical trialRandomized controlled triallawInternal medicineChemoprophylaxismedicineCorticosteroidbusinessmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct

Medical management of Crohn's disease

2011

The medical approach to Crohn's disease has been modified in recent years thanks to the introduction of new therapies, like biologics. Also, well-designed studies and systematic reviews have allowed better evaluation of the role of old drugs like steroids and immunosuppressors. This review aims to evaluate the recent evidence on the medical approach to Crohn's disease in the different settings of the disease.Randomized controlled trials and meta-analyses were included in the review. The research on all the studies discussed was based on the Cochrane Library, Medline and Embase, using the following medical subject headings: Crohn's disease, clinical trial, therapy, 5-aminosalicylic acid, ste…

Budesonidemedicine.medical_specialtyPathologyAnti-Inflammatory AgentsMEDLINEDiseaseCochrane LibraryManagement of Crohn's diseaselaw.inventionCrohn DiseaseRandomized controlled trialAdrenal Cortex HormoneslawmedicineHumansPharmacology (medical)BudesonideIntensive care medicineBone Marrow TransplantationPharmacologyBiological ProductsTumor Necrosis Factor-alphabusiness.industryRemission InductionGeneral Medicinemedicine.diseaseAnti-Bacterial AgentsIntestinesClinical trialAminosalicylic AcidsMethotrexateTreatment OutcomeSystematic reviewPurinesbusinessImmunosuppressive Agentsmedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

ESRA19-0543 Analgesic effects of dexamethasone when given perineurally or intravenously in the upper arm bone fracture and shoulder joint surgery

2019

Background and aims Shoulder surgery is associated with severe pain. Pain delays rehabilitation and lowers quality of life. Finding adjuvants to the LA to improve analgesia and facilitate mobilization has been the focus of researchers recently. The aim of this work was to investigate which administration methods—dexamethasone perineural or intravenously—prevents pain more effectively. Methods Prospective, randomized study conducted at Hospital of Traumatology and Orthopaedics after ethics committee approval. Study involved 75 patients with upper limb fracture or shoulder joint surgery in RA and GA. Group I: Bupivacaine 0.25% 70 mg + Dexamethasone 8 mg perineurally Group II: Bupivacaine 0.25…

Bupivacainemedicine.medical_specialtyShoulder surgerybusiness.industrymedicine.medical_treatmentAnalgesicTraumatologylaw.inventionSurgeryRandomized controlled trialOpioidlawMorphineMedicinebusinessDexamethasonemedicine.drugE-Poster Viewing Abstracts
researchProduct

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

2015

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effecti…

CHRONIC KIDNEY-DISEASERANDOMIZED CONTROLLED-TRIALSMuscle symptomPLACEBO-CONTROLLED TRIALMedicine General & InternalMuscular DiseasesCardiovascular DiseaseGeneral & Internal MedicineDefinition; Muscle symptoms; Risk factors; Statin intolerance; Cardiovascular Diseases; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Pharmacology (medical); Medicine (all)Humansdefinitionrisk factorsPharmacology (medical)CORONARY-HEART-DISEASETHROMBOTIC THROMBOCYTOPENIC PURPURAcardiovascular diseasesFATTY LIVER-DISEASEDyslipidemiasPRIMARY BILIARY-CIRRHOSISScience & TechnologyMuscular DiseasePOST-HOC ANALYSISMedicine (all)nutritional and metabolic diseases1103 Clinical SciencesCOA-REDUCTASE INHIBITORSDyslipidemiaDENSITY-LIPOPROTEIN CHOLESTEROLCardiovascular Diseasesmuscle symptomslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorRisk factorPosition PaperHydroxymethylglutaryl-CoA Reductase InhibitorsLife Sciences & BiomedicineHumanstatin intoleranceArchives of Medical Science : AMS
researchProduct

Randomized, Double-Blind, Clinically Controlled Trial of Intranasal Calcitonin Treatment in Patients with Hip Fracture

2002

The objective of this study was to evaluate the short-term outcome of intranasal calcitonin treatment of elderly hip fracture patients on pain, bone loss, functional recovery, and length of hospital stay. In addition, we wanted to compare the effect of calcitonin with placebo on fusion of hip fractures treated with internal fixation using a screw or a nail. In a randomized, double-blind, clinically controlled trial, 260 independently living patients (aged 65 years or older) with acute hip fracture were randomly assigned to intranasal calcitonin 200 IU daily for 3 months or matching placebo nasal spray. Analyses were completed on an intention-to-treat basis. Three months after the operation,…

CalcitoninMalemedicine.medical_specialtyVisual analogue scaleEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisPainPlacebolaw.inventionFracture Fixation InternalEndocrinologyDouble-Blind MethodRandomized controlled trialBone DensitylawActivities of Daily LivingFracture fixationmedicineHumansInternal fixationOrthopedics and Sports MedicineBone ResorptionAdministration IntranasalOsteoporosis PostmenopausalAgedPain MeasurementAged 80 and overFracture HealingHip fractureHip Fracturesbusiness.industryLength of Staymedicine.diseaseSurgeryCalcitoninFemalebusinessCalcified Tissue International
researchProduct